Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP)’s stock price rose 7.6% during trading on Monday . The stock traded as high as $9.32 and last traded at $9.25. Approximately 2,698,496 shares were traded during trading, an increase of 5% from the average daily volume of 2,581,285 shares. The stock had previously closed at $8.60.
Wall Street Analyst Weigh In
AUPH has been the subject of several recent research reports. StockNews.com initiated coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, October 5th. They set a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 22nd.
Aurinia Pharmaceuticals Trading Up 7.7 %
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in Aurinia Pharmaceuticals by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,798 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth about $31,000. Geneos Wealth Management Inc. grew its position in Aurinia Pharmaceuticals by 54.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,142 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Aurinia Pharmaceuticals by 3,036.8% during the 1st quarter. Nisa Investment Advisors LLC now owns 4,266 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 4,130 shares during the period. Finally, Focused Wealth Management Inc bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at approximately $48,000. 39.64% of the stock is owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
- Five stocks we like better than Aurinia Pharmaceuticals
- The “How” and “Why” of Investing in 5G Stocks
- The most upgraded stocks in November have two things in common
- How to Start Investing in Real Estate
- Monday.com rocked earnings like it’s the weekend
- Canada Bond Market Holiday: How to Invest and Trade
- Plan to own one retailer? Make it this one
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.